IMMUNOVANT, INC. (IMVT) Operating cash flow 2019–2026
IMMUNOVANT, INC. (IMVT) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$407.3MFY2026 · since FY2019: -$28.5M → -$407.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$407.3M | -8.4% |
| FY2025 | -$375.9M | -75.5% |
| FY2024 | -$214.2M | -13.8% |
| FY2023 | -$188.2M | -77.4% |
| FY2022 | -$106.1M | -27.3% |
| FY2021 | -$83.3M | -56.2% |
| FY2020 | -$53.4M | -86.9% |
| FY2019 | -$28.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More IMVT financial trends
IMVT RevenueIMVT Net incomeIMVT Net marginIMVT Gross profitIMVT Gross marginIMVT Operating incomeIMVT Operating marginIMVT Free cash flowIMVT Capital expendituresIMVT Return on equityIMVT Stock buybacksIMVT Dividends paidIMVT Total assetsIMVT Total liabilitiesIMVT Shareholders’ equityIMVT overview →